Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCORI’s Slow Start On Comparative Research May Protect It From Political Heat

Executive Summary

The Patient-Centered Outcomes Research Institute’s slow ramp-up to being in a position to fund comparative research projects may actually help it survive a heated political environment in an election year.

You may also be interested in...



PCORI Repeal Rhetoric Has Declined In Congress – Wilensky

During the run-up to the passing of the Affordable Care Act, the Patient-Centered Outcomes Research Institute was the target of much Republican criticism. But based on her interactions with congressional members, Project HOPE’s Gail Wilensky says there’s no desire now on Capitol Hill to end the institute’s activities.

Lack Of Cost-Effectiveness Analysis For Products In Development Could Affect Company Valuations, Attorney Mahinka Says

With payers playing a more prominent role in determining access to drugs, developers will need to focus more on the comparative value of a drug throughout the development cycle, including cost. That value equation also will become an important part of the M&A landscape, attorney Stephen Mahinka says.

PCORI Committee Unveils Preliminary Framework For Developing Research Agenda

The first version of the framework consists of a list of features that research projects ultimately selected for funding will include, but no specific agenda items were offered. Cmte. also updates national priorities.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel